**Question:** AKT1 E17K somatic mutation is associated with

A. Colorectal cancer
B. Breast cancer
C. Prostate cancer
D. Endometrial cancer

**Core Concept:**

The AKT1 E17K somatic mutation refers to a genetic alteration involving the AKT1 gene, which encodes the AKT1 protein, a serine/threonine kinase involved in regulating cellular processes such as cell growth, survival, and glucose uptake. The E17K mutation occurs at amino acid residue 17, where the lysine (K) substitution replaces the wild-type glutamic acid (E). This mutation has been associated with increased AKT1 activity and impaired insulin signaling, leading to uncontrolled cell growth and cancer development.

**Why the Correct Answer is Right:**

The AKT1 E17K mutation is primarily associated with endometrial cancer (Option D). While it is known to have implications in other cancers like colorectal, breast, and prostate cancers, the strongest evidence links this mutation to endometrial cancer, which is a type of cancer affecting the endometrium (inner lining) of the uterus. This association is supported by numerous studies that have demonstrated the involvement of the AKT1 gene in endometrial cancer progression and its role in impairing insulin signaling.

**Why Each Wrong Option is Incorrect:**

A. Colorectal cancer (Option A) is predominantly linked to mutations in KRAS, NRAS, and PIK3CA genes rather than AKT1 E17K. While AKT1 may contribute to colorectal carcinogenesis, the primary drivers of colorectal cancer are different.

B. Breast cancer (Option B) is primarily associated with mutations in BRCA1, BRCA2, and TP53 genes, rather than AKT1 E17K mutation. AKT1 is involved in breast cancer, but other genes play a more significant role in driving this type of cancer.

C. Prostate cancer (Option C) is typically driven by mutations in AR, TP53, and RB1 genes, not AKT1 E17K mutation. Although AKT1 may contribute to prostate cancer, other genes are more commonly implicated.

**Clinical Pearl:**

The AKT1 E17K mutation is a relatively rare genetic alteration, and the association with specific cancers is not absolute. However, understanding the role of AKT1 in cancer progression can aid in recognizing potential cases where this mutation may be implicated, facilitating appropriate diagnostic and therapeutic approaches in clinical practice.